<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Reoviridae</italic>: Despite the successful implementation of vaccine programs against rotavirus (RV) starting in 2006, it continues to be the leading cause of viral diarrheal mortality in children under the age of 5 globally, causing approximately 200,000 deaths per year [
 <xref rid="B32-viruses-12-00904" ref-type="bibr">32</xref>]. To date, there are two internationally licensed oral RV vaccines [
 <xref rid="B33-viruses-12-00904" ref-type="bibr">33</xref>,
 <xref rid="B34-viruses-12-00904" ref-type="bibr">34</xref>]: the monovalent Rotarix and the pentavalent RotaTeq. Additional newer-generation RV vaccines are licensed in individual countries [
 <xref rid="B33-viruses-12-00904" ref-type="bibr">33</xref>]. RV group A is the most common cause of AGE in countries without effective RV vaccination programs, causing significant childhood morbidity and mortality. RV is generally understood to target the mature enterocytes of the small intestine, likely mediating diarrheal illness via both direct effects on the epithelium and indirect effects from host responses [
 <xref rid="B35-viruses-12-00904" ref-type="bibr">35</xref>].
</p>
